Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma (CBIO)
NASDAQ:CBIO
Total Valuation
Crescent Biopharma has a market cap or net worth of $264.27M. The enterprise value is $1.71M.
Market Cap$264.27M
Enterprise Value$1.71M
Share Statistics
Crescent Biopharma has 27,556,767 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,556,767
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Crescent Biopharma’s return on equity (ROE) is 4.62 and return on invested capital (ROIC) is -264.45%.
Return on Equity (ROE)4.62
Return on Assets (ROA)-2.01
Return on Invested Capital (ROIC)-264.45%
Return on Capital Employed (ROCE)-2.64
Revenue Per Employee0.00
Profits Per Employee-1.15M
Employee Count33
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Crescent Biopharma is ―. Crescent Biopharma’s PEG ratio is -13.03.
PE Ratio―
PS Ratio0.00
PB Ratio-103.72
Price to Fair Value-103.72
Price to FCF-51.61
Price to Operating Cash Flow-32.71
PEG Ratio-13.03
Income Statement
In the last 12 months, Crescent Biopharma had revenue of 0.00 and earned -71.47M in profits. Earnings per share was -0.59.
Revenue0.00
Gross Profit0.00
Operating Income-68.76M
Pretax Income-71.47M
Net Income-71.47M
EBITDA0.00
Earnings Per Share (EPS)-0.59
Cash Flow
In the last 12 months, operating cash flow was -48.49M and capital expenditures -726.00K, giving a free cash flow of -49.22M billion.
Operating Cash Flow-48.49M
Free Cash Flow-49.22M
Free Cash Flow per Share-1.79
Dividends & Yields
Crescent Biopharma pays an annual dividend of $0.24, resulting in a dividend yield of ―
Dividend Per Share$0.24
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change-63.40%
50-Day Moving Average12.60
200-Day Moving Average15.08
Relative Strength Index (RSI)31.36
Average Volume (3m)145.41K
Important Dates
Crescent Biopharma upcoming earnings date is Apr 30, 2026, After Close (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Crescent Biopharma as a current ratio of 3.62, with Debt / Equity ratio of 1.49%
Current Ratio3.62
Quick Ratio3.62
Debt to Market Cap0.02
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Crescent Biopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Crescent Biopharma EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -51.70.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-51.70
EV to Operating Cash Flow-51.71
Balance Sheet
Crescent Biopharma has $133.26M in cash and marketable securities with $1.74M in debt, giving a net cash position of $131.52M billion.
Cash & Marketable Securities$133.26M
Total Debt$1.74M
Net Cash$131.52M
Net Cash Per Share$4.77
Tangible Book Value Per Share-$0.24
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Crescent Biopharma is $30.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.14
Price Target Upside214.29% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-100.00%
EPS Growth Forecast-0.58%